REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors

Key Inclusion Criteria:

≥18 years of age (≥20 years of age for patients enrolled in Japan)
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Has histologically or cytologically confirmed cancer that meets criteria as defined in the protocol
Expansion Cohorts only: Is anti-programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) naïve, defined as never having previously been treated with a drug that targets the PD-1
Has at least 1 lesion that meets study criteria as defined in the protocol
Willing to provide tumor tissue from newly obtained biopsy (at a minimum core biopsy) from a tumor site that has not been previously irradiated
Has adequate organ and bone marrow function as defined in the protocol
In the judgement of the investigator, has a life expectancy of at least 3 months

Key Exclusion Criteria:

Is currently participating in another study of a therapeutic agent
Has participated in any study of an investigational agent or an investigational device within 4 weeks of the first administration of study drug as defined in the protocol
Has received treatment with an approved systemic therapy within 4 weeks of the first administration of study drug or has not yet recovered (ie, grade 1 or baseline) from any acute toxicities
Has received recent anti-epidermal growth factor receptor (EGFR) antibody therapy as defined in the protocol
Has received radiation therapy or major surgery within 14 days of the first administration of study drug or has not recovered (ie, grade 1 or baseline) from adverse events
Has received any previous systemic, non-immunomodulatory biologic therapy within 4 weeks of first administration of study drug.
Has had prior anti-cancer immunotherapy within 5 half-lives prior to study drug as defined in the protocol
Has second malignancy that is progressing or requires active treatment as defined in the protocol
Has any condition requiring ongoing/continuous corticosteroid therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 1-2 weeks prior to the first dose of study drug as defined in the protocol
Has ongoing or recent (within 5 years) evidence of significant autoimmune disease or any other condition that required treatment with systemic immunosuppressive treatments as defined in the protocol
Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression
Has encephalitis, meningitis, organic brain disease (eg, Parkinson's disease) or uncontrolled seizures within 1 year prior to the first dose of study drug
Has any ongoing inflammatory skin disease as defined in the protocol NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply